Analysts, along with management, discuss the size of the OTC opportunity for the company in ADHD and the potential for strategic partnerships in the US and globally on a conference call to be held on October 6 at 12 pm hosted by LifeSci Capital.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AKLI:
- Akili CEO Eddie Martucci transitions to board chair, Matt Franklin to succeed
- Akili participates in a conference call with LifeSci Capital
- Akili sees FY23 total operating expenses $55M-$60M
- Akili plans to transition to a non-prescription model, reduce headcount by 40%
- Akili reports Q2 revenue $114,000, consensus $240,000